Tags: stem | cell | treatment | leg | pain | placenta-based | intermittent

Stem Cell Treatment for Leg Pain Shows Success

Stem Cell Treatment for Leg Pain Shows Success
(Copyright Stock Photo Secrets)

Wednesday, 13 June 2018 08:35 AM

Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Pluristem said its PLX-PAD treatment reduced incidence of revascularization and improved patients’ mobility.

IC - muscle pain and weakness brought on by exercise - is usually associated with early-stage peripheral artery disease and if not treated can progress to critical limb ischemia (CLI), where patients are at risk of leg amputation and death.

The Phase II study was designed to evaluate the safety, efficacy and optimal dosing regimen for PLX-PAD cells in patients with IC. Enrollment took place at 28 clinical sites in the United States, Germany, South Korea and Israel.

The study's results also validate the design of Pluralism's advanced Phase III trial for CLI, the company said.

© 2018 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC). Pluristem said its PLX-PAD treatment reduced...
stem, cell, treatment, leg, pain, placenta-based, intermittent, claudication
143
2018-35-13
Wednesday, 13 June 2018 08:35 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved